Pacer Advisors Inc. Acquires Shares of 15,460 Hims & Hers Health, Inc. (NYSE:HIMS)

Pacer Advisors Inc. purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 15,460 shares of the company’s stock, valued at approximately $374,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its stake in Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after buying an additional 883,230 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after purchasing an additional 482,177 shares during the last quarter. Carnegie Investment Counsel bought a new stake in Hims & Hers Health during the 3rd quarter valued at approximately $5,531,000. Blueshift Asset Management LLC grew its holdings in Hims & Hers Health by 834.8% in the 3rd quarter. Blueshift Asset Management LLC now owns 245,013 shares of the company’s stock valued at $4,513,000 after buying an additional 218,804 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Hims & Hers Health by 15.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock worth $30,714,000 after buying an additional 218,566 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on HIMS. BTIG Research began coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Piper Sandler boosted their price objective on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Monday, January 6th. Needham & Company LLC upped their price objective on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Citigroup downgraded Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their target price for the stock from $24.00 to $25.00 in a research report on Friday, January 10th. Finally, Morgan Stanley began coverage on Hims & Hers Health in a report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target for the company. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and an average target price of $25.13.

Hims & Hers Health Trading Up 7.7 %

Shares of Hims & Hers Health stock opened at $41.94 on Wednesday. The stock has a market capitalization of $9.16 billion, a price-to-earnings ratio of 95.32 and a beta of 1.35. The firm’s 50-day moving average price is $29.58 and its two-hundred day moving average price is $22.86. Hims & Hers Health, Inc. has a 1-year low of $8.51 and a 1-year high of $41.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.04) EPS. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity at Hims & Hers Health

In other news, insider Soleil Boughton sold 4,153 shares of Hims & Hers Health stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $35.30, for a total transaction of $146,600.90. Following the completion of the sale, the insider now owns 161,497 shares in the company, valued at $5,700,844.10. The trade was a 2.51 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Oluyemi Okupe sold 142,886 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.93, for a total value of $4,276,577.98. Following the completion of the sale, the chief financial officer now directly owns 112,186 shares of the company’s stock, valued at approximately $3,357,726.98. This trade represents a 56.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,156,332 shares of company stock valued at $33,853,055 over the last ninety days. 17.71% of the stock is owned by insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.